Breast density, benign breast disease, and risk of breast cancer over time

2021 ◽  
Author(s):  
Marta Román ◽  
Javier Louro ◽  
Margarita Posso ◽  
Rodrigo Alcántara ◽  
Lupe Peñalva ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Density ◽  
Benign Breast Disease ◽  
Breast Disease ◽  
Over Time

scholarly journals Benign Breast Disease, Mammographic Breast Density, and the Risk of Breast Cancer

2013 ◽  
Vol 105 (14) ◽  
pp. 1043-1049 ◽  
Author(s):  
Jeffrey A. Tice ◽  
Ellen S. O’Meara ◽  
Donald L. Weaver ◽  
Celine Vachon ◽  
Rachel Ballard-Barbash ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Density ◽  
Benign Breast Disease ◽  
Breast Disease ◽  
Mammographic Breast Density

scholarly journals Benign breast disease and changes in mammographic breast density

2021 ◽  
Vol 23 (1) ◽  
Author(s):  
Laura L. Reimers ◽  
Mandy Goldberg ◽  
Parisa Tehranifar ◽  
Karin B. Michels ◽  
Barbara A. Cohn ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Density ◽  
Benign Breast Disease ◽  
Breast Disease ◽  
Mammographic Breast Density ◽  
Computer Assisted ◽  
First Birth ◽  
Dense Area ◽  
Nulliparous Women ◽  
Using Data

Abstract Background Mammographic breast density (MBD) and benign breast disease (BBD) are two of the strongest risk factors for breast cancer. Understanding trends in MBD by age and parity in women with BBD is essential to the clinical management and prevention of breast cancer. Methods Using data from the Early Determinants of Mammographic Density (EDMD) study, a prospective follow-up study of women born in 1959–1967, we evaluated MBD in 676 women. We used linear regression with generalized estimating equations to examine associations between self-reported BBD and MBD (percent density, dense area, and non-dense area), assessed through a computer-assisted method. Results A prior BBD diagnosis (median age at diagnosis 32 years) was reported by 18% of our cohort. The median time from BBD diagnosis to first available study mammogram was 9.4 years (range 1.1–27.6 years). Women with BBD had a 3.44% higher percent MBD (standard error (SE) = 1.56, p-value = 0.03) on their first available mammogram than women without BBD. Compared with parous women without BBD, nulliparous women with BBD and women with a BBD diagnosis prior to first birth had 7–8% higher percent MBD (β = 7.25, SE = 2.43, p-value< 0.01 and β = 7.84, SE = 2.98, p-value = 0.01, respectively), while there was no difference in MBD in women with a BBD diagnosis after the first birth (β = −0.22, SE = 2.40, p-value = 0.93). Conclusion Women with self-reported BBD had higher mammographic breast density than women without BBD; the association was limited to women with BBD diagnosed before their first birth.

scholarly journals Breast Density and Benign Breast Disease: Risk Assessment to Identify Women at High Risk of Breast Cancer

2015 ◽  
Vol 33 (28) ◽  
pp. 3137-3143 ◽  
Author(s):  
Jeffrey A. Tice ◽  
Diana L. Miglioretti ◽  
Chin-Shang Li ◽  
Celine M. Vachon ◽  
Charlotte C. Gard ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Assessment ◽  
Primary Prevention ◽  
High Risk ◽  
Breast Density ◽  
Benign Breast Disease ◽  
Risk Model ◽  
Breast Biopsy ◽  
Breast Disease ◽  
History Of

Purpose Women with proliferative breast lesions are candidates for primary prevention, but few risk models incorporate benign findings to assess breast cancer risk. We incorporated benign breast disease (BBD) diagnoses into the Breast Cancer Surveillance Consortium (BCSC) risk model, the only breast cancer risk assessment tool that uses breast density. Methods We developed and validated a competing-risk model using 2000 to 2010 SEER data for breast cancer incidence and 2010 vital statistics to adjust for the competing risk of death. We used Cox proportional hazards regression to estimate the relative hazards for age, race/ethnicity, family history of breast cancer, history of breast biopsy, BBD diagnoses, and breast density in the BCSC. Results We included 1,135,977 women age 35 to 74 years undergoing mammography with no history of breast cancer; 17% of the women had a prior breast biopsy. During a mean follow-up of 6.9 years, 17,908 women were diagnosed with invasive breast cancer. The BCSC BBD model slightly overpredicted risk (expected-to-observed ratio, 1.04; 95% CI, 1.03 to 1.06) and had modest discriminatory accuracy (area under the receiver operator characteristic curve, 0.665). Among women with proliferative findings, adding BBD to the model increased the proportion of women with an estimated 5-year risk of 3% or higher from 9.3% to 27.8% (P < .001). Conclusion The BCSC BBD model accurately estimates women's risk for breast cancer using breast density and BBD diagnoses. Greater numbers of high-risk women eligible for primary prevention after BBD diagnosis are identified using the BCSC BBD model.

scholarly journals Serum levels of oxidative stress marker malondialdehyde in breast cancer patients in relation to pathohistological factors, estrogen receptors, menopausal status, and age

2018 ◽  
Vol 8 (3) ◽  
pp. 154-161
Author(s):  
Jasmina Gubaljevic ◽  
Nahida Srabović ◽  
Adlija Jevrić-Čaušević ◽  
Adaleta Softić ◽  
Adi Rifatbegović ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Lymph Nodes ◽  
Cancer Patients ◽  
Benign Breast Disease ◽  
Menopausal Status ◽  
Serum Levels ◽  
Breast Disease ◽  
Breast Cancer Patients ◽  
Node Metastases

Introduction: The aim of this study was to determine the serum levels of malondialdehyde (MDA) in patients with invasive breast cancer in relation to its serum levels in patients with benign breast disease, and to investigate correlation between MDA serum levels with pathohistological prognostic factors (tumor size, lymph node involvement, and histologic grade [HG]), estrogen receptor (ER) status, and with breast cancer patient’s age and menopausal status. Methods: A total of 43 with well-documented invasive breast cancer were included in this study: 27 with positive axillary’s lymph nodes, and 16 with negative axillary’s lymph nodes, and 39 patients with findings of benign breast diseases. MDA determination in serum of breast cancer and benign breast disease patients was performed by the fluorimetric method, immunohistochemical staining was performed for ER, and routine pathohistological examination was conducted for pathohistological factors. Results: MDA serum levels in breast cancer patients were significantly higher than MDA serum levels in benign breast disease patients (p = 0.042). No statistically significant difference between MDA serum levels in breast cancer patients with and without lymph node metastases was found (p = 0.238). No statistically significant correlations between MDA serum levels and tumor size (p = 0.256), HG (p = 0.124), or number of positive lymph nodes (0.113) were found. A statistically significant correlation between serum MDA levels and ages of breast cancer patients with lymph node metastases was found (p = 0.006). Conclusion: Obtained results support the importance of MDA in the carcinogenesis of breast cancer. According to our findings, serum level of MDA could not be a useful prognostic factor in breast cancer.

Sign in / Sign up

Export Citation Format

Share Document